Most Read Articles
Jairia Dela Cruz, 26 Jun 2018
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Stephen Padilla, 20 Sep 2018
Romosozumab therapy for 12 months is well tolerated and effective in increasing spine and hip bone mineral density (BMD) in men with osteoporosis, according to a recent study.

Prazosin cuts rate of drinking in patients with alcohol use disorder

10 Sep 2018
How to identify doctors hooked on drugs and alcohol

The α-1 adrenergic receptor antagonist prazosin appears to be an effective treatment for alcohol use disorder, according to a recent study.

“Prazosin holds promise as a harm-reduction pharmacologic treatment for alcohol use disorder and deserves further evaluation by independent research groups,” the authors said.

A total of 92 participants with alcohol use disorder but without post-traumatic stress disorder were randomized to receive prazosin or placebo in a 12-week double-blind study. Medication was titrated to a target dosing of 4 mg in morning and in the afternoon and 8 mg at bedtime by the end of week 2.

Medical management was the behavioural platform. Data on alcohol consumption were provided by participants daily. The authors assessed the impact of prazosin vs placebo on number of drinks per week, number of drinking days per week and number of heavy drinking days per week using generalized linear mixed-effects models.

Of the participants, 80 completed the titration and were included in the primary analyses. A significant association was seen between condition and week for both number of drinks and number of heavy drinking days. Participants in the prazosin condition had a greater reduction in the rate of drinking and the probability of heavy drinking compared with those in the placebo condition over time.

In addition, there was a higher incidence of drowsiness and oedema among participants in the prazosin vs the placebo condition.

“Current medications for alcohol use disorder do not target brain noradrenergic pathways. Theoretical and preclinical evidence suggests that noradrenergic circuits may be involved in alcohol reinforcement and relapse,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 26 Jun 2018
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Stephen Padilla, 20 Sep 2018
Romosozumab therapy for 12 months is well tolerated and effective in increasing spine and hip bone mineral density (BMD) in men with osteoporosis, according to a recent study.